Informed consent—the idea that patients have the right to make their own decisions about their medical treatments—first appeared in court rulings in the early 20th century. It was codified into law in the 1970s and 1980s and is now sacrosanct.
“The point of informed consent is to demonstrate that the physician or the provider has given the patient all the material information they need to make an...
Informed consent—the idea that patients have the right to make their own decisions...
In a tight labor market employers must use every tool at their disposal to land the...
Urmen Desai, MD, learned at an early age the rewards of caring for others. His parents...
Giving and receiving gifts is a normal occurrence in most people’s personal and...
Canfield Scientific’s VECTRA H2 offers an all-in-one portable lightweight 3D...
Topix Pharmaceuticals' Replenix Pure Hydration Plumping Lip Treatment Broad...
Capture consistent before-and-after images with FotoFinder’s new Automated...
Epionce Renewal Calming Cream from Episciences soothes sensitive, eczema-...
 A literature review performed by Rawaa M. Almukhtar, MD, and Sabrina G. Fabi, MD, and published in Plastic and Reconstructive Surgery (January 2019) revealed that botulinum toxin injections to the masseter muscle effectively recontour the lower face and may reduce aging-related maxillary...
|
 Pulse Biosciences has announced positive results from a clinical efficacy study of its proprietary Nano-Pulse Stimulation (NPS) technology for the treatment of sebaceous hyperplasia (SH). Non-thermal NPS delivers nanosecond duration energy pulses to disrupt the functions of internal cell...
|
A literature review performed by Rawaa M. Almukhtar, MD, and Sabrina G. Fabi, MD, and published in Plastic and Reconstructive Surgery (January 2019) revealed that botulinum toxin injections to the masseter muscle effectively recontour the lower face and may reduce aging-related maxillary concerns.
The researchers performed a PubMed search for articles on botulinum toxin type A treatments to the masseter, which included treatment for muscle hypertrophy and aging-related changes to the lower face. Their findings showed that botulinum toxin type A can safely be injected into the lower posterior aspect of the masseter muscle. All adverse events cited were minimal and short lasting. Aesthetically, the treatment decreases muscle bulk and reshapes the lower face. The studies also showed improvement in quality-of-life measures, such as a decrease in pain and symptoms of grinding and jaw clenching. The injections decreased stress on the maxillary and mandibular bones and may help prevent tooth loss and progressive bone resorption of the lower face.
Image copyright Getty Images
Pulse Biosciences has announced positive results from a clinical efficacy study of its proprietary Nano-Pulse Stimulation (NPS) technology for the treatment of sebaceous hyperplasia (SH). Non-thermal NPS delivers nanosecond duration energy pulses to disrupt the functions of internal cell structures while maintaining the outer cell membrane, initiating a cascade of events within the cell that results in regulated cell death.
The Sebaceous Hyperplasia clinical study enrolled 73 patients, each with up to four facial lesions. Patients received one or two NPS treatments per lesion at five centers in the U.S. The study’s primary success measurement was the degree of clearance as rated by the investigator at the final study visit.
Initial data indicate that 221 of 222 (99.5%) facial SH lesions treated with NPS energy were rated as clear or mostly clear by clinical investigators 60 days post treatment. Approximately 92% (n=203) of treated lesions were assessed as clear or mostly clear after a single NPS treatment. Patients rated 78 percent of lesion outcomes at study end as satisfied or mostly satisfied. In some cases, mild to moderate posttreatment hyperpigmentation was noted, particularly in patients with higher...
Cutera CEO James Reinstein has resigned from his position as president, CEO and board member. The Cutera board of directors has appointed the company’s current chief operating officer, Jason Richey, as Interim CEO.
Richey joined Cutera in July 2018 after serving a dual role as president of North America and general manager of the neuromodulation franchise of LivaNova PLC’s $5 billion global medical device business. Previously he spent 17 years at Cyberonics, where he served as vice president and general manager of the company’s International business.
The board has formed a CEO search committee that will be chaired by Director Gregory Barrett. The committee will retain an external executive search firm to assist it in conducting a national search for a permanent CEO.
The American Society for Dermatologic Surgery (ASDS) and American Society for Dermatologic Surgery Association (ASDSA) were recognized with 14 awards—including three Platinums—in the 2015 MarCom Awards.
The MarCom Awards competition is administered and judged by the Association of Marketing and Communication Professionals, selecting winners “whose work serves as a benchmark for the industry.” The 2015 competition received about 6,500 entries representing more than a dozen countries.
The Platinum Award—MarCom’s top honor—was presented to ASDS in three categories: Currents... more »
Merz Aesthetics has begun commercial shipment of the Cellfina System, indicated for long-term improvement in the appearance of cellulite in the buttocks and thighs, to aesthetic practices in the U.S.
Cellfina combines proprietary technology with minimally invasive subcision to treat the primary structural cause of dimpled cellulite. Results of the procedure last at least two years—in clinical trials, patient satisfaction with their treatment results improved from 94% at one year to 96% at the two-year mark. The most common side effects reported were soreness, tenderness and bruising... more »
